Clinical Trial Update: Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating autologous HBV-TCR T cell therapy LioCyx-M for hepatocellular carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• LioCyx-M (HBV-TCR T cell therapy)

Snippet

Sponsor: Lion TCR Pte. Ltd. | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: RECRUITING